The 2007 WHO classification of tumors of the central nervous system - What has changed?

Current Opinion in Neurology

Volumn 21, Issue 6, 2008, Pages 720-727

  Rousseau, Audrey ^a   Mokhtari, Karima ^a   Duyckaerts, Charles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Central nervous system; Genetics; Histology; Tumor; WHO classification

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; TUMOR MARKER; VINCRISTINE;

ANAPLASTIC CARCINOMA; ASTROCYTOMA; CANCER GRADING; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; CHOROID PLEXUS PAPILLOMA; CHOROID PLEXUS TUMOR; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL PRACTICE; CRANIAL NERVE TUMOR; CRANIOPHARYNGIOMA; CYTOGENETICS; DIAGNOSTIC IMAGING; DRUG SENSITIVITY; EPENDYMOMA; GANGLIONEUROMA; GENE DELETION; GENETIC DISORDER; GENOMICS; GIANT CELL TUMOR; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; GOLD STANDARD; GRANULAR CELL TUMOR; HEMANGIOBLASTOMA; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MEDULLOBLASTOMA; MENINGIOMA; MOLECULAR GENETICS; MORPHOLOGY; NERVE TUMOR; NEURILEMOMA; NEUROECTODERM TUMOR; NEUROEPITHELIOMA; NEUROFIBROMA; NOMENCLATURE; OLIGODENDROGLIOMA; ONCOCYTOMA; PAPILLOMA; PARAGANGLIOMA; PINEAL BODY TUMOR; REVIEW; RHABDOID TUMOR; SPINAL CORD TUMOR; SUBEPENDYMOMA; TERATOMA; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION;

BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENOMICS; HUMANS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 56749100474     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328312c3a7     Document Type: Review

References (44)

1. Louis DN, Ohgaki H, Wiestier OD, Cavenee WK, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon, IARC; 2007. A must-read and must-have book for anyone involved in the brain tumor field.
2. Kleihues P, Cavenee WK, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon, IARC; 2000.
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109. This article is a review of the 2007 WHO classification of tumors of the central nervous system by the authors of the latest edition themselves.
4. Lellouch-Tubiana A, Boddaert N, Bourgeois M, et al. Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol 2005; 15:281-286.
5. Wang M, Tihan T, Rojiani AM, et al. Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol 2005; 64:875-881.
6. Preusser M, Hoischen A, Novak K, et al. Angiocentric glioma: report of clinicopathologic and genetic findings in 8 cases. Am J Surg Pathol 2007; 31: 1709-1718.
7. Brat DJ, Scheithauer BW, Eberhart CG, Burger PC. Extraventricular neurocytomas: pathologic features and clinical outcome. Am J Surg Pathol 2001; 25:1252-1260.
8. Komori T, Scheithauer BW, Anthony DC, et al. Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. Am J Surg Pathol 1998; 22:1171-1183.
9. Komori T, Scheithauer BW, Hirose T. A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol 2002; 26:582-591.
10. Preusser M, Dietrich W, Czech T, et al. Rosette-forming glioneuronal tumor of the fourth ventricle. Acta Neuropathol 2003; 106:506-508.
11. Prayson RA, Abramovich CM. Glioneuronal tumor with neuropil-like islands. Hum Pathol 2000; 31:1435-1438.
12. Keyvani K, Rickert CH, von Wild K, Paulus W. Rosetted glioneuronal tumor: a case with proliferating neuronal nodules. Acta Neuropathol 2001; 101:525-528.
13. Barbashina V, Salazar PA, Ladanyi M, Rosenblum MK. Glioneuronal tumor with neuropil-like islands (GNTI). A report of 8 cases with chromosome 1p/19q deletion analysis. Am J Surg Pathol 2007; 31:1196-1202.
14. Jouvet A, Fauchon F, Liberski P, et al. Papillary tumor of the pineal region. Am J Surg Pathol 2003; 27:505-512.
15. Fèvre-Montange M, Hasselblatt M, Figarella-Branger D, et al. Prognosis and histopathologic features in papillary tumors of the pineal region: a retrospective multicenter study of 31 cases. J Neuropath Exp Neurol 2006; 65:1004-1011.
16. Brat DJ, Scheithauer BW, Staugaitis SM, et al. Pituicytoma: a distinctive low-grade glioma of the neurohypophysis. Am J Surg Pathol 2000; 24:362-368.
17. Roncaroli F, Scheithauer BW, Cenacchi G, et al. 'Spindle cell oncocytoma' of the adenohypophysis: a tumor of folliculostellate cells? Am J Surg Pathol 2002; 26:1048-1055.
18. Kloub O, Perry A, Tu PH, et al. Spindle cell oncocytoma of the adenohypophysis: report of two recurrent cases. Am J Surg Pathol 2005; 29:247-253.
19. Jeibmann A, Hasselblatt M, Gerss J, et al. Prognostic implications of atypical histologic features in choroid plexus papilloma. J Neuropath Exp Neurol 2006; 65:1069-1073.
20. Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly-diagnosed high-grade gliomas. J Clin Oncol 2006; 24:5419-5426.
21. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24:2715-2722.
22. Kleihues P, Burger PC, Scheithauer BW, editors. Histological typing of tumours of the central nervous system. World Health Organization international histological classification of tumours. Heidelberg, Springer; 1993.
23. Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008; 122:1778-1786. This study demonstrates that whole-genome analysis using array comparative genomic hybridization (CGH) allows identification of distinct genetic subtypes of gliomas and that such subtypes correlate with distinct biologic behaviors.
24. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003; 62:111-126.
25. Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004; 70:161-181.
26. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65:988-994.
27. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1 p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66:9852-9861.
28. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-1479.
29. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18:636-645.
30. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7:839-845.
31. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22:3133-3138.
32. Giannini C, Burger PC, Berkey BA, et al. Anaplastic Oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in intergroup radiation therapy oncology group trial 9402. Brain Pathol 2008; 18:360-369. The authors show that glial tumors with classic histopathologic features of oligodendroglioma respond to PCV-based chemotherapy and are associated with a longer survival compared with glial neoplasms lacking such classic features.
33. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 2008; 67:1-15. This comprehensive review focuses on three predictive molecular markers (1p/19q status in oligodendroglial tumors, MGMT promoter methylation status in glioblastomas and EGFR signaling pathway activation in glioblastomas). The authors formulate recommendations for routine and clinical trial testing based on the status of assays and the diagnostic, prognostic, or predictive abilities of the biomarkers.
34. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64:6892-6899.
35. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004; 108:49-56.
36. Kros JM. From expert opinion to evidence-based: changes in the gold standard of primary brain tumor diagnosis. J Pathol 2007; 213:1-3.
37. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 15:1871-1874.
38. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
39. Everhard S, Kaloshi G, Crinière E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006; 60:740-743.
40. 6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106:1759-1765.
41. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 2008; 16:59-65.
42. Preusser M, Janzer RC, Felsberg J, et al. Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008 [Epub ahead of print]
43. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008; 10:332-337.
44. Bailey P, Cushing H. A classification of tumors of the glioma group on a histogenetic basis with a correlation study of prognosis. Philadelphia: Lippincott; 1926.